Increasing Efficacy of Treatment in Patients with Steatohepatitis

E.G. Manzhalii, V.E. Kondratiuk

Abstract


This paper presents the results of a study of patients with nonalcoholic steatohepatitis, alcoholic steatohepatitis, and drug-induced liver injury. In patients with liver injury, changes in intestinal microflora were marked. After a combination therapy of this pathology with L-ornithine L-aspartate and symbiotic, an improvement of biochemical, clinical indicators was observed, as well as a decrease in fatty degeneration, reduction of elastographic indicators of liver fibrosis. The introduction of the drug formulation L-ornithine L-aspartate and symbiotic in the complex of conservative treatment of steatohepatitis help to prevent complications and increase the treatment efficacy of these diseases.


Keywords


L-ornithine L-aspartate; Lactobacillus casei; Bifidobacterium longum; fructooligosaccharides; steatohepatitis; endotoxins

Full Text:

PDF

References


Bataller R., Gao B. Liver fibrosis in alcoholic liver disease // Semin. Liver Dis. 2015; 35: 146.

Baykova I.E., Nikitin I.G. [Drug liver] // Ross. Med. Zhurn. 2009; 1. — ​Article in Russian.

Bueverov A.O. et al. [Essential phospholipids in the treatment of mixed origin steatohepatitis] // Klin. perspekt. gastroenterol. gepatol. 2008; 1. — ​Article in Russian.

Weiler S., Merz M., Kullak-Ublick G.A. Drug-induced liver injury: the dawn of biomarkers? // F1000Prime Rep. 2015; 7: 34.

Drapkina О.М., Korneeva O.H., Ivashkin V.T. [Therapy of nonalcoholic steatohepatitis and metabolic syndrome: focus on essential phospholipids] // Lechaschiy Vrach 2010; 2. — ​Article in Russian.

Gerok V., Blum Kh.E. [Liver and biliary system], M.: МЕDpress-inform, 2009, p. 199. — ​Article in Russian.

Gong G. et al. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats // PLoS One 2014; 9: e89450.

Khomeriki S.G., Khomeriki N.M. [Alcoholic liver disease: pathogenesis, morphological manifestations, differential diagnosis and pathogenetic approaches to therapy] // Gastroenterologiya 2012; 1. — ​Article in Russian.

Machado M.V., Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know // World J. Gastroenterol. 2014; 20: 12956.

Neuman M.G. et al. Alcoholic and non-alcoholic steatohepatitis // Exp. Mol. Pathol. 2014; 97: 492.

Polunina T.E., Maev I.V. [Nonalcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment] // Gastroente­rologiya 2012; 1. — ​Article in Russian.

Velkov V.V. [Non-invasive biomarkers of fibrosis. Good-bye, biopsy?] // Kliniko-laboratornyy consilium 2009; 30. — ​Article in Russian.

Weismuller T.J., Lankisch T.O. [Biliary diseases — ​new insights and developments] // Dtsch. Med. Wochenschr. 2011; 136: S713. — ​Article in German.




DOI: https://doi.org/10.22141/2312-413x.3.12.2016.81705

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru